Pipeline as recorded in the Atlas on Aug 25, 2026. Companies revise pipelines frequently — verify against the company's own materials and regulatory filings.
In one paragraph
CRISPR Therapeutics was co-founded by one of the scientists who worked out how to program CRISPR in the first place. With Vertex Pharmaceuticals it developed Casgevy, the first CRISPR-based medicine approved anywhere. Its other work spans off-the-shelf CAR-T cancer therapies, in vivo liver editing and regenerative medicine.
CRISPR Therapeutics AG is a Swiss-American gene-editing company founded in 2013 by Emmanuelle Charpentier with Rodger Novak and Shaun Foy. Its Vertex-partnered exagamglogene autotemcel became the first approved CRISPR-based therapy. The pipeline spans allogeneic CAR-T (CTX112 and successors), in vivo liver programmes and regenerative medicine, with cardiovascular and autoimmune indications added in recent years.
Not investment advice
This profile is educational information compiled from public disclosures. It is not a recommendation to buy, sell or hold any security, and it is not a view on the company's prospects. Biotechnology is highly speculative and most clinical programmes fail.
Full disclaimers →
Written by The CRISPR Atlas editorial teamLast updated Aug 25, 2026
Connected in the Atlas
Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.
